Independent data monitoring committees help to ensure patient safety and uphold trial integrity. In Central Nervous System (CNS) studies, independent data monitoring is especially critical due to challenges such as patient enrollment, rater variability, and placebo response rates. The right DMC provider can help overcome these challenges and optimize the clinical research approach.

The following case study illustrates how a clinical-stage biotechnology company developing novel medicines to address CNS diseases was concerned about the management and assessment of their study data. To navigate this critical phase, the biotech selected Axio, a Cytel company, as an independent statistical center to provide DMC support for their ongoing studies.

Download the case study below to learn how partnering with Axio enabled the client to expedite their DMC safety reports, all while maintaining the highest standards of patient safety and trial integrity.

Share Via